Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6147023rdf:typepubmed:Citationlld:pubmed
pubmed-article:6147023lifeskim:mentionsumls-concept:C0034493lld:lifeskim
pubmed-article:6147023lifeskim:mentionsumls-concept:C0027792lld:lifeskim
pubmed-article:6147023lifeskim:mentionsumls-concept:C0013303lld:lifeskim
pubmed-article:6147023lifeskim:mentionsumls-concept:C1304890lld:lifeskim
pubmed-article:6147023lifeskim:mentionsumls-concept:C1979804lld:lifeskim
pubmed-article:6147023lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:6147023pubmed:issue2lld:pubmed
pubmed-article:6147023pubmed:dateCreated1984-8-29lld:pubmed
pubmed-article:6147023pubmed:abstractTextPrevious studies have shown that adrenergic and cholinergic neural pathways mediate duodenal serotonin (5-HT) release from the mucosal surface after a luminal acid stimulus. To examine the overall neural contribution to 5-HT release, we studied the effects of tetrodotoxin (TTX), a nerve-conduction blocker, added to mucosal and/or serosal surfaces of rabbit duodenal mucosa in a modified Ussing chamber at both neutral and acid (pH 5) luminal pH. A specific radioimmunoassay was used to measure 5-HT. TTX (2 X 10(-7) M) increased mucosal 5-HT release significantly at luminal pH 7.4 and 5 when it was added to both mucosal and serosal surfaces (2.7- and 1.9-fold at pH 7.4 and pH 5, respectively; p less than 0.05 for each) or when it was added to the serosal surface only (3.4- and 1.8-fold; p less than 0.02 and p less than 0.01, respectively). TTX added only to the mucosal surface, however, reduced 5-HT release by 48.5% at pH 5 (p less than 0.01) and had no effect at pH 7.4. Since adenosine triphosphate (ATP) and vasoactive intestinal polypeptide are the two proposed mediators of a nonadrenergic, noncholinergic inhibitory neural system, we studied the effects of each on mucosal 5-HT release. While vasoactive intestinal polypeptide had no significant effect at either pH, ATP (10(-7)M) reduced acid-stimulated 5-HT release by approximately 50% (p less than 0.02). We conclude that a nonadrenergic, noncholinergic neural pathway that is inhibitory to mucosal 5-HT release resides primarily on the basal surface of mucosal cells. ATP is the most likely neurotransmitter involved in this response.lld:pubmed
pubmed-article:6147023pubmed:languageenglld:pubmed
pubmed-article:6147023pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6147023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147023pubmed:statusMEDLINElld:pubmed
pubmed-article:6147023pubmed:monthAuglld:pubmed
pubmed-article:6147023pubmed:issn0039-6060lld:pubmed
pubmed-article:6147023pubmed:authorpubmed-author:WuJJlld:pubmed
pubmed-article:6147023pubmed:authorpubmed-author:DonowitzMMlld:pubmed
pubmed-article:6147023pubmed:authorpubmed-author:KellumJ MJMlld:pubmed
pubmed-article:6147023pubmed:issnTypePrintlld:pubmed
pubmed-article:6147023pubmed:volume96lld:pubmed
pubmed-article:6147023pubmed:ownerNLMlld:pubmed
pubmed-article:6147023pubmed:authorsCompleteYlld:pubmed
pubmed-article:6147023pubmed:pagination139-45lld:pubmed
pubmed-article:6147023pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:meshHeadingpubmed-meshheading:6147023-...lld:pubmed
pubmed-article:6147023pubmed:year1984lld:pubmed
pubmed-article:6147023pubmed:articleTitleEnteric neural pathways inhibitory to rabbit duodenal serotonin release.lld:pubmed
pubmed-article:6147023pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6147023pubmed:publicationTypeIn Vitrolld:pubmed